Comprehensive Medication Management for Hypertension in the United States: A Scoping Review of Therapeutic, Humanistic, Safety and Economic Outcomes
Emerging research has shown that pharmacist-led comprehensive medication management (CMM) can be an effective strategy for controlling hypertension. A synthesis of the evidence on the overall effects of CMM on clinical, quality, and economic outcomes could help inform and contribute to improvements in programming and practice. Presently, such a synthesis is limited in the literature. To address this gap, we conducted a scoping review of CMM effects on these outcomes, organized by 4 domains: therapeutic, humanistic, safety and economic. Using predefined search terms for articles on studies published between 2010 and 2024, we performed a literature search utilizing these terms to search the MEDLINE, Cochrane Library and CINAHL databases. For each of the identified studies, we applied a multi-stage screening process to extract data, chart results, and synthesize findings. The process took into account methodology of study design, patient population involved, CMM implementation, relevance of outcomes to clinical improvement, and factors that were deemed relevant to study selection. In total, 49 experimental, observational, and simulation-based studies were included in the scoping review. The synthesis focused on outcomes most frequently reported and those rigorously evaluated by the studies in the review. They included clinical measures of blood pressure reduction and control, frequency and duration of healthcare visits, and changes in medication therapy regimen and medication adherence. Overall, CMM interventions were found to have significantly favorable effects on systolic blood pressure reduction, hypertension control, and medication changes. Other outcomes, which showed positive effects, included self-reported patient experience and behaviors, emergency department visits, hospitalizations, mortality, and program costs and related savings from implementing a CMM program. Some results, however, were mixed. For example, a number of studies reported outcomes data without significance testing and many generally lacked consistent characterization of their programming and implementation processes. Future research and practice evaluations should include these elements in their documentation. Furthermore, a more consistent approach to implementing CMM in the field may lead to better support of program delivery fidelity, helping to optimize CMM, moving it from demonstrated efficacy to intervention effectiveness in the real world.
Authors
- Dalia Regos-Stewart (ORCID: https://orcid.org/0009-0008-6484-2764)
- Evans D. Pope (ORCID: https://orcid.org/0000-0002-0838-2766)
- Steven Chen (ORCID: https://orcid.org/0000-0003-3239-4975)
- Stefanie Weber (ORCID: https://orcid.org/0000-0002-2023-8193)
- Noel C. Barragan (ORCID: https://orcid.org/0000-0003-1076-5341)
- Tony Kuo (ORCID: https://orcid.org/0000-0002-4120-8559)
- Devin Lee
- Luis Larios
- Alexander Cantres
Institutions
- Wisconsin Department of Health Services (US)
- University of Southern California (US)
- Los Angeles County Department of Public Health (US)
- University of California, Los Angeles (US)
- UCLA Health (US)
- Southern California Clinical and Translational Science Institute (US)
- UCLA Clinical and Translational Science Institute
Publication Details
- Journal
- Encyclopedia
- Published
- 2025-08-30
- DOI
- https://doi.org/10.3390/encyclopedia5030133
- Citations
- 1
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.22
Funders
- Los Angeles County Department of Public Health
- Centers for Disease Control and Prevention